Arena Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

02.05.18	Arena Pharmaceuticals to Release First Quarter 2018 Financial Results and Provide Corporate Update on Tuesday, May 8 (PR Newswire)
01.05.18	Arena Pharmaceuticals and Outpost Medicine Enter into Licensing Agreement for Undisclosed Novel Compound (PR Newswire)
13.04.18	FDA Nod For Innovus' Kit, PLSE Soars On SK Data, Keep An Eye On ARNA (RTTNews)
12.04.18	Arena Pharmaceuticals Announces Phase 2 Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the International Society for Heart and Lung Transplantation Annual Meeting (PR Newswire)
03.04.18	Survey: 74% Of Physicians Favor Medicaid Work Requirements (PR Newswire)
24.03.18	Arena Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference on March 27 (PR Newswire)
22.03.18	GERN Turning Heads, ARQL To Present Data In Apr., Mark Your Calendar For PTN (RTTNews)
20.03.18	ARNA Soars After-hours, Remoxy Now 2 Steps Away From Approval, APLS On Watch (RTTNews)
19.03.18	Arena Pharmaceuticals Reports Positive Phase 2 Results from the OASIS Trial for Etrasimod in Patients with Ulcerative Colitis (PR Newswire)
18.03.18	An Ear To The Pharma: 11 Stocks To Watch This Week (RTTNews)
14.03.18	EARNINGS SUMMARY: Details of Arena Pharmaceutical Inc. Q4 Earnings Report (RTTNews)
14.03.18	Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results (PR Newswire)
08.03.18	Arena Pharmaceuticals to Announce Fourth Quarter and Full-Year 2017 Financial Results and Provide Corporate Update on Wednesday, March 14 (PR Newswire)
02.03.18	Will These 10 Pharma Stocks Surge Or Crash? (RTTNews)
01.03.18	Arena Pharmaceuticals to Present Phase 1 and Preclinical Data on APD371 in Development for Treatment of Pain Associated with Crohn's Disease at American Pain Society Annual Scientific Summit (PR Newswire)
16.02.18	Arena Pharmaceuticals Announces Changes to Board of Directors (PR Newswire)
06.02.18	Arena Pharmaceuticals to Present at Upcoming Investor Conferences (PR Newswire)
22.01.18	Arena Pharmaceuticals to Host Key Opinion Leader Event on S1P Modulation and Etrasimod in Autoimmune Diseases on January 29 in New York City (PR Newswire)
12.01.18	CBMG Giving Back Its Gains, ARNA To Report Data In Q1, AXON Continues To Fall (RTTNews)
04.01.18	ARWR Hits A High, URGN Begins 2018 In Style, ARNA To Report Data In Q1 (RTTNews)
05.12.17	Arena Pharmaceuticals and Everest Medicines Enter into Development and Commercialization Partnership for Ralinepag and Etrasimod in China (PR Newswire)
05.12.17	Arena Pharmaceuticals and Everest Medicines Enter into Development and Commercialization Partnership for Ralinepag and Etrasimod in China (PR Newswire)
13.11.17	FDA Nod For BMY's Sprycel, ARNA To Report Data In Q1, MYL Delists From TASE (RTTNews)
10.11.17	Arena Pharmaceuticals Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for Ulcerative Colitis (PR Newswire)
07.11.17	EARNINGS SUMMARY: Details of Arena Pharmaceutical Inc. Q3 Earnings Report (RTTNews)
31.10.17	Arena Pharmaceuticals to Present at the Credit Suisse Healthcare Conference on November 8 (PR Newswire)
30.10.17	Arena Pharmaceuticals to Release Third Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, November 7 (PR Newswire)
19.10.17	Arena Pharmaceuticals Announces Late Breaking Presentation of Positive Phase 2 Results with Ralinepag in Patients with Pulmonary Arterial Hypertension at the American College of Chest Physicians... (PR Newswire)
06.09.17	Arena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at International Congress of the European Respiratory Society (PR Newswire)
22.08.17	Arena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at European Society of Cardiology Congress (PR Newswire)
16.08.17	Biotech Stock Performance Review -- Aralez Pharma, Arena Pharma, Arrowhead Pharma, and Aviragen Therapeutics (PR Newswire)
07.08.17	EARNINGS SUMMARY: Details of Arena Pharmaceutical Inc. Q2 Earnings Report (RTTNews)
07.08.17	Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial Results (PR Newswire)
31.07.17	Arena Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
13.07.17	Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock (PR Newswire)
12.07.17	Biotech Stocks Ride Momentum in Anticipation of Favorable Governmental Policy Environment (PR Newswire)
12.07.17	Biotech Stocks Ride Momentum in Anticipation of Favorable Governmental Policy Environment (PR Newswire)
12.07.17	Gainers & Losers Of July 11: ARNA, FOLD, VSTM, TOCA, GTHX... (RTTNews)
11.07.17	Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock (PR Newswire)
11.07.17	Arena Pharmaceuticals Remains Sharply Higher After Early Rally (RTTNews)
11.07.17	ARNA Heartened By Phase II Trial, BMY To Face FDA In Nov., Concert Back In Play (RTTNews)
11.07.17	Arena Pharma Stock Surges On Positive Hypertension-drug Study (RTTNews)
10.07.17	Arena Pharmaceuticals Reports Positive Topline Phase 2 Results for Ralinepag in Patients with Pulmonary Arterial Hypertension (PR Newswire)
29.06.17	Arena Pharmaceuticals Completes Trial Comparing Once-Daily, Extended Release Formulation of Ralinepag with Twice-Daily, Immediate Release Formulation in Normal Healthy Volunteers (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sika	231.70	1.58 %	K V
CieFinRichemont	124.55	1.51 %	K V
Holcim	91.00	1.40 %	K V
ABB	50.92	1.27 %	K V
Swiss Re	131.75	1.23 %	K V
Sonova Hldg	301.30	0.17 %	K V
Lonza Grp	527.20	0.15 %	K V
Novartis	93.27	0.00 %	K V
Givaudan	3’876.00	-0.13 %	K V
Roche Hldg G	254.70	-0.31 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Arena Pharmaceuticals Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten